Drug intelligence / Profile preview

VM-PSY-006

Development stage: Unknown
Lead developer: VivaMed
Modality: Small Molecules

Overview

VM-PSY-006 is a cannabinoid-based small molecule therapeutic candidate under development by VivaMed BioPharma. It is specifically being investigated for the treatment of Post-Traumatic Stress Disorder (PTSD). While the specific molecular target has not been disclosed by the company, cannabinoid-based drugs typically interact with the endocannabinoid system to modulate stress and anxiety responses. The program is currently in the IND-enabling or Phase 1 stage of development.

Beyond the preview

Go deeper on VM-PSY-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VM-PSY-006.

Explore the full profile